Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection

Stock News06-25

Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration on June 24, 2026. The clinical trial application for the injection HDM2017 submitted by the subsidiary has been approved.

The announcement indicates that HDM2017 specifically targets and binds to the CDH17-positive antigen expressed on the surface of tumor cells through its antibody component. This antigen-mediated internalization allows the antibody-drug conjugate (ADC) to enter the tumor cell, where the linker is cleaved, releasing the cytotoxic payload intracellularly to exert its anti-tumor effect. Additionally, the bystander effect of HDM2017 further enhances its tumor-killing efficacy.

Preclinical study results demonstrate that HDM2017 possesses favorable drug-like properties, safety, and effectiveness. The compound has shown potent anti-tumor activity in efficacy models for CDH17-positive cancers, including colorectal cancer, pancreatic cancer, and gastric cancer. It was also well-tolerated in animal studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178671040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178671040","market":"nz","top_or_hot":-1,"title":"Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection","media":"Stock News","content":"<p>Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration on June 24, 2026. The clinical trial application for the injection HDM2017 submitted by the subsidiary has been approved.<br><br>The announcement indicates that HDM2017 specifically targets and binds to the CDH17-positive antigen expressed on the surface of tumor cells through its antibody component. This antigen-mediated internalization allows the antibody-drug conjugate (ADC) to enter the tumor cell, where the linker is cleaved, releasing the cytotoxic payload intracellularly to exert its anti-tumor effect. Additionally, the bystander effect of HDM2017 further enhances its tumor-killing efficacy.<br><br>Preclinical study results demonstrate that HDM2017 possesses favorable drug-like properties, safety, and effectiveness. The compound has shown potent anti-tumor activity in efficacy models for CDH17-positive cancers, including colorectal cancer, pancreatic cancer, and gastric cancer. It was also well-tolerated in animal studies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-25 18:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration on June 24, 2026. The clinical trial application for the injection HDM2017 submitted by the subsidiary has been approved.<br><br>The announcement indicates that HDM2017 specifically targets and binds to the CDH17-positive antigen expressed on the surface of tumor cells through its antibody component. This antigen-mediated internalization allows the antibody-drug conjugate (ADC) to enter the tumor cell, where the linker is cleaved, releasing the cytotoxic payload intracellularly to exert its anti-tumor effect. Additionally, the bystander effect of HDM2017 further enhances its tumor-killing efficacy.<br><br>Preclinical study results demonstrate that HDM2017 possesses favorable drug-like properties, safety, and effectiveness. The compound has shown potent anti-tumor activity in efficacy models for CDH17-positive cancers, including colorectal cancer, pancreatic cancer, and gastric cancer. It was also well-tolerated in animal studies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1178671040","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178671040","pubTimestamp":1782383921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0175":"白马股","000963":"华东医药","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0183":"MSCI概念","BK0209":"零售","BK0132":"高送转概念","BK0188":"融资融券","BK0196":"行业龙头","BK0187":"一线龙头"},"translate_title":"华东医药子公司HDM2017注射液获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1},"content_text":"Huadong Medicine Co., Ltd. has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration on June 24, 2026. The clinical trial application for the injection HDM2017 submitted by the subsidiary has been approved.The announcement indicates that HDM2017 specifically targets and binds to the CDH17-positive antigen expressed on the surface of tumor cells through its antibody component. This antigen-mediated internalization allows the antibody-drug conjugate (ADC) to enter the tumor cell, where the linker is cleaved, releasing the cytotoxic payload intracellularly to exert its anti-tumor effect. Additionally, the bystander effect of HDM2017 further enhances its tumor-killing efficacy.Preclinical study results demonstrate that HDM2017 possesses favorable drug-like properties, safety, and effectiveness. The compound has shown potent anti-tumor activity in efficacy models for CDH17-positive cancers, including colorectal cancer, pancreatic cancer, and gastric cancer. It was also well-tolerated in animal studies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178671040","isCrawlerRequest":true}